Vera Therapeutics
VERA
31 hedge funds and large institutions have $252M invested in Vera Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 7 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
41% more funds holding
Funds holding: 22 → 31 (+9)
36% more capital invested
Capital invested by funds: $186M → $252M (+$66.3M)
0.94% more ownership
Funds ownership: 69.21% → 70.15% (+0.94%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.46M |
| 3 |
JP Morgan Chase
New York
|
+$1.41M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.35M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$7.8M |
| 2 |
Millennium Management
New York
|
-$1.08M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$894K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$611K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$265K |
VERA Hedge Fund Activity: Q3 2021 in Review
31 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q3 2021, worth a combined $252M — up 36% from $186M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VERA positions and 7 closed out — a net gain of 9 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $5.6M. The largest seller was Octagon Capital Advisors, cutting an estimated $7.8M.
- 31 institutional investors held Vera Therapeutics (VERA) as of Q3 2021, up from 22 in Q2 2021.
- Funds reported $252M of Vera Therapeutics stock for Q3 2021, up 36% quarter-over-quarter.
- 16 funds opened new Vera Therapeutics positions in Q3 2021 and 7 closed out, a net change of +9 holders.
- The largest Vera Therapeutics buyer in Q3 2021 was BlackRock, an estimated $5.6M added.
- The largest Vera Therapeutics seller in Q3 2021 was Octagon Capital Advisors, an estimated $7.8M sold.
Based on aggregated 13F filings for Q3 2021.